Edition:
United States

Omeros Corp (OMER.O)

OMER.O on Consolidated Issue listed on NASDAQ Global Market

19.81USD
17 Nov 2017
Change (% chg)

$-0.14 (-0.70%)
Prev Close
$19.95
Open
$19.96
Day's High
$20.41
Day's Low
$19.31
Volume
931,011
Avg. Vol
879,088
52-wk High
$27.09
52-wk Low
$8.71

Chart for

About

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria... (more)

Overall

Beta: 3.43
Market Cap(Mil.): $950.95
Shares Outstanding(Mil.): 48.00
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 197.02 15.79
EPS (TTM): -- -- --
ROI: -- -10.12 12.01
ROE: -- -37.71 15.91

BRIEF-Omeros Corp reports Q3 loss per share $0.16

* Omeros Corporation reports third quarter 2017 financial results

Nov 09 2017

BRIEF-OMEROS REPORTS ADDITIONAL POSITIVE DATA FOR OMS721

* OMEROS REPORTS ADDITIONAL AND CONSISTENTLY POSITIVE DATA FOR OMS721 IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY

Oct 26 2017

BRIEF-Omeros Corp amends term loan agreement

* On Oct 11, co entered amendment no. 1 to loan agreement, which amended term loan agreement, dated October 26, 2016​

Oct 17 2017

BRIEF-OMEROS ANNOUNCES SETTLEMENT OF INFRINGEMENT SUIT AGAINST ANDA FILER PAR

* OMEROS ANNOUNCES SETTLEMENT OF INFRINGEMENT SUIT AGAINST ANDA FILER PAR

Oct 05 2017

BRIEF-Omeros announces pricing of public offering of common stock

* Omeros announces pricing of public offering of common stock

Aug 15 2017

BRIEF-Omeros announces public offering of common stock

* Says offering 3.00 million common shares Source text for Eikon: Further company coverage:

Aug 14 2017

BRIEF-Omeros Corporation Q2 loss per share $0.33

* Omeros corporation reports second quarter 2017 financial results

Aug 08 2017

BRIEF-FDA grants orphan drug designation to Omeros’ OMS721

* FDA grants Orphan Drug Designation to Omeros’ OMS721 for treatment of IGA Nephropathy

Aug 04 2017

BRIEF-Omeros says FDA grants breakthrough therapy designation to OMS721 for treatment of IgA Nephropathy

* FDA grants breakthrough therapy designation to Omeros’ MASP-2 inhibitor OMS721 for the treatment of IgA Nephropathy

Jun 13 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $138.00 -0.87
Novartis AG (NOVN.S) CHF83.30 +0.90
Pfizer Inc. (PFE.N) $35.37 -0.19
Roche Holding Ltd. (ROG.S) CHF230.10 +1.10
Roche Holding Ltd. (RO.S) CHF233.30 +1.30
Merck & Co., Inc. (MRK.N) $55.20 +0.03
Bayer AG (BAYGn.DE) €107.55 -0.35
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €75.43 -0.54
Eli Lilly and Co (LLY.N) $82.89 -0.55

Earnings vs. Estimates